|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-05S2
|
$37,430
|
$374
|
Curran, Walter
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-05
|
$1,396,397
|
$13,964
|
Curran, Walter
|
EMORY UNIVERSITY
|
|
UW Comprehensive Cancer Center Support
|
2P30CA014520-39
|
$4,133,528
|
$82,671
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-39S1
|
$37,429
|
$749
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-39S2
|
$122,414
|
$2,448
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
Tumor-produced TNF alpha as an inducer of immune resistance and tumor survival
|
5R01CA136663-04
|
$310,286
|
$310,286
|
Levitskaia, Elena
|
JOHNS HOPKINS UNIVERSITY
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$336,277
|
$30,265
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Tulane Medical/Cancer Center Minority-Based Community Clinical Oncology Program
|
5U10CA167782-02
|
$663,700
|
$6,637
|
Robinson, William
|
TULANE UNIVERSITY OF LOUISIANA
|
|
Translational Genomics of MicroRNAs in Neuroblastoma
|
5K08CA136979-05
|
$161,773
|
$161,773
|
Cole, Kristina
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
The Role of Stroma-derived Soluble TbetaRIII in Neuroblastoma
|
5F30CA168043-02
|
$31,596
|
$31,596
|
Knelson, Erik
|
DUKE UNIVERSITY
|
|
The Role of KIR and FcR Genotype in the Efficacy of mAb and IL2 Immunotherapy
|
5R01CA166105-02
|
$318,902
|
$191,341
|
SONDEL, PAUL
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
The Role of Caspase-8 in Neuroblastoma Tumorigenesis
|
5R01CA067938-15
|
$360,423
|
$360,423
|
ZAMBETTI, GERARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
The Genetic Basis of Neuroblastoma Tumorigenesis
|
2R01CA124709-06
|
$630,730
|
$630,730
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
3R01CA148688-03S1
|
$46,634
|
$46,634
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
5R01CA148688-03
|
$341,338
|
$341,338
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
5R01CA140198-05
|
$311,233
|
$311,233
|
Mosse, YAEL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Targeting High-risk Neuroblastoma using high through put siRNA screening
|
ZIA BC 010806
|
$347,473
|
$243,231
|
Khan, Javed
|
CCR (NCI)
|
|
Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB)
|
5U24CA114766-08
|
$1,684,917
|
$336,983
|
RAMIREZ, NILSA
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
|
St. Vincent Hospital Regional Cancer Center CCOP
|
5U10CA095968-12
|
$755,168
|
$7,552
|
Jaslowski, Anthony
|
ST. VINCENT HOSPITAL
|
|
Sphingosine-1-Phosphate Pathway Based Therapy for Neuroblastoma
|
5R01CA168903-02
|
$324,678
|
$324,678
|
FERRER, FERNANDO
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-27S9
|
$3,858,688
|
$77,174
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
South Texas Pediatric Minority Based CCOP
|
5U10CA052771-23
|
$435,423
|
$26,125
|
LANGEVIN, ANNE-MARIE
|
UNIV OF TX HSC, SA
|
|
Signaling Mechanisms of EphrinB1 in Cell Adhesion, Migration and Invasion
|
ZIA BC 010958
|
$482,268
|
$48,227
|
Daar, Ira
|
CCR (NCI)
|
|
Role of Trk Receptors in the Development and Function of Non-neuronal Structures
|
ZIA BC 010391
|
$597,349
|
$59,735
|
Tessarollo, Lino
|
CCR (NCI)
|
|
Role of Neurotrophins in the Development of the Mammalian Nervous System
|
ZIA BC 010390
|
$597,349
|
$119,470
|
Tessarollo, Lino
|
CCR (NCI)
|
|
RGB-286638 as a radiation sensitizer
|
ZIA BC 011454
|
$170,118
|
$42,530
|
Haglund, Karl
|
CCR (NCI)
|
|
Regulation of MDM2 auto-ubiquitination and molecular targeting
|
2R01CA123490-06A1
|
$251,191
|
$62,798
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
Regulation of Differentiation of Pediatric Embryonal Tumors- Neuroblastoma
|
ZIA BC 010788
|
$515,383
|
$309,230
|
Thiele, Carol
|
CCR (NCI)
|
|
Regional Oncology Research Center
|
3P30CA006973-50S1
|
$43,750
|
$438
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-50S2
|
$50,000
|
$500
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
5P30CA006973-50
|
$6,540,575
|
$65,406
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Radiological Physics Center
|
5U10CA010953-45
|
$2,786,631
|
$55,733
|
Followill, David
|
UT MD ANDERSON CANCER CTR
|
|
Quantitative SPECT for Targeted Radionuclide Therapy
|
5R01CA109234-08
|
$368,839
|
$92,210
|
FREY, ERIC
|
JOHNS HOPKINS UNIVERSITY
|
|
Quantitative and Spatial Optimization for Designing Cancer Therapeutics
|
5F32CA168274-02
|
$53,942
|
$26,971
|
Robinson-Mosher, Avram
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
|
Quality Assurance Review Center
|
3U10CA029511-33S1
|
$1,946,959
|
$38,939
|
FITZGERALD, THOMAS
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
Pretherapy 124I-MIBG Dosimetry for Planning 131I-MIBG Neuroblastoma Therapy
|
5R01CA154561-03
|
$387,639
|
$387,639
|
SEO, YOUNGHO
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Predicting toxicity and success of anti-GD2 immunotherapy of neuroblastoma
|
5R01CA164132-02
|
$302,328
|
$302,328
|
YU, ALICE
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
2R01CA129377-06
|
$239,246
|
$239,246
|
DeClerck, Yves
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in neuroblastoma
|
1R01CA168699-01A1
|
$284,061
|
$284,061
|
Kang, Min
|
TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
|
|
Pharmacogenetics in children with high-risk neuroblastoma
|
1R03CA178104-01
|
$98,452
|
$98,452
|
MCCUNE, JEANNINE
|
UNIVERSITY OF WASHINGTON
|
|
Perinatal, Familial, and Neighborhood Risk Factors for Childhood Cancer
|
1R03CA171017-01A1
|
$49,680
|
$4,968
|
Crump, Casey
|
LUND UNIVERSITY
|
|
Pediatric Oncology Branch Clinical Care and Education
|
ZIE BC 011516
|
$3,012,786
|
$150,639
|
Merchant, Melinda
|
CCR (NCI)
|
|
Pediatric Cancer, Family Conflict and Child Adjustment
|
5R01CA134794-04
|
$313,829
|
$78,457
|
KATZ, LYNN
|
UNIVERSITY OF WASHINGTON
|
|
Pathophysiologic Consequences of Neurotrophin Activation of Trk in Neuroblastoma
|
ZIA BC 010789
|
$277,514
|
$249,762
|
Thiele, Carol
|
CCR (NCI)
|
|
Pathogenic Roles of SHP2 & PTPRD Tyrosine Phosphatases in High-Risk Neuroblastoma
|
1K99CA178189-01
|
$122,683
|
$122,683
|
zhu, Shizhen
|
MAYO CLINIC ROCHESTER
|
|
Optimizing Immunotherapy for Neuroblastoma after BMT
|
5R01CA100030-10
|
$277,478
|
$277,478
|
JOHNSON, BRYON
|
MEDICAL COLLEGE OF WISCONSIN
|
|
Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma
|
1R01CA172067-01
|
$197,757
|
$197,757
|
DuBois, Steven
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Oklahoma CCOP
|
2U10CA045459-27
|
$424,982
|
$4,250
|
LOCKHART, JAMES
|
WARREN CANCER RESEARCH FOUNDATION
|
|
Ochsner Community Clinical Oncology Program
|
5U10CA035272-29
|
$563,756
|
$5,638
|
Fuloria, Jyotsna
|
OCHSNER CLINIC FOUNDATION
|
|
New Mexico Minority Based Community Clinical Oncology Program
|
2U10CA086780-14
|
$795,607
|
$15,912
|
ROYCE, MELANIE
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
Total relevant funding to Neuroblastoma for this search: $18,808,908
|